Diacerein: Recent insight into pharmacological activities and molecular pathways - 28/10/20
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
| pages | 9 |
| Iconographies | 5 |
| Vidéos | 0 |
| Autres | 0 |
Graphical abstract |
The Key processes and pharmacological activities by which the diacerein performs its therapeutic and beneficial role.
The beneficial effects and potential therapeutic activities of diacerein.
Highlights |
• | Diacerein has a great efficacy with a safety profile in osteoarthritis treatment. |
• | Anti-inflammatory, antioxidant and anti-apoptosis are key events used by the drug. |
• | It limits the risk of ulcerative colitis, gonads injury and cervical hyperkeratosis. |
• | It has a therapeutic role in cancer, kidney injury, diabetes mellites and heart. |
• | Gout and breast cancer could benefit from synergy between diacerein and other drugs. |
Abstract |
Diacerein is a symptomatic slow-acting drug in osteoarthritis (SYSADOA) and the active metabolite is rhein. It is a non-steroidal anti-inflammatory drug with unique pharmacological properties as anti-oxidant and anti-apoptosis. Diacerein has recently shown to have a potential role by mediating anti-inflammatory as well as anti-oxidant and anti-apoptosis in kidney injury, diabetes mullites, and a beneficial effect on pain relief. It may have a therapeutic role in cancer, ulcerative colitis, testicular injury and cervical hyperkeratosis. Furthermore, diacerein has a valuable addition in combination therapy as a synergetic agent. This review, the first of its kind, highlights the proposed roles of diacerein in osteoarthritis and discusses recent results supporting its emerging roles with a particular focus on how these new insights may facilitate the rational development of diacerein for targeted therapies in the future.
Le texte complet de cet article est disponible en PDF.Abbreviations : SYSADOA, COX-2, DKK, IL-1β, iNOS, MMP, NO, PGE2, uPA, MAPK, MEK/ER, FAK, AP-1, GLP-1, DPP-4, ER, mRNA, IL-6, PRAC, EMA, TNF-α, pIR-βp, pAkt, STAT-3, AKI, PTP1B, IRS-1, MDA, HO-1, Nrf2, ROS, AQPs, NF-κB, T2DM, NAAA, PEA, AEA, CXCL-13, TG, DRG, IBD, UC, NSAIDs, CdCl2, NLRP3, TIR, DN, SST, NSCLC, MTX, NAFLD, EBS
Keywords : Diacerein, Anti-inflammatory, Anti-oxidant, Anti-apoptosis, Cytokines
Plan
Vol 131
Article 110594- novembre 2020 Retour au numéro
Article précédent
- Cancer neoantigen: Boosting immunotherapy
- Peijia Xu, Haiqing Luo, Ying Kong, Wing-Fu Lai, Liao Cui, Xiao Zhu
- Vitamin C: A stem cell promoter in cancer metastasis and immunotherapy
- Jingwen Fu, Zhaoyi Wu, Jianfeng Liu, Tianfu Wu
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.
Déjà abonné à cette revue ?